Amii is pleased to work with SpectraCann, a drug-detection technology company based in Edmonton. The project objective is to advance SpectraCann’s innovative detection technologies powered by quantum optics, leveraging Amii’s leading expertise and talent in artificial intelligence.

The project will focus on current drug detection challenges that involve lower volatility substances, low concentrations, or the presence of confounding chemicals. To overcome these challenges, the project team aims to develop an AI classification model that leverages machine learning techniques and considers the spectral properties of the data.

“We’re excited to work with SpectraCann to continue their work in innovative drug detection,” said Stephanie Enders, Chief Delivery Officer. “The advanced exploration of machine learning applied to THC identification in infrared spectra represents significant progress at the intersections of AI and quantum optics with positive implications for many sectors including healthcare, law enforcement, industry regulation, and consumer safety.”

Leyla Kara, Chief Executive Officer at SpectraCann, commented, “Our team is eager to partner with Amii and push the boundaries of what is possible to achieve in drug detection domain using our platform technology. By integrating AI into our THC Breathalyzer and other detection products, we aim to enhance the precision and speed of our solutions, making them more effective in meeting the challenges of industry and governments in real-world applications.”